PF-05214030

PF-05214030 is a TRPV4 antagonist (IC50: 4 and 27nM for hTRPV4 and rTRPV4 respectively) . PF-05214030 reverses the reduction in bladder capacity caused by intravesical infusion of a TRPV4 agonist[1][2].

Product Specifications

CAS Number

[1669444-50-1]

UNSPSC

12352005

Target

TRP Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/pf-05214030.html

Purity

99.81

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

N#CC1=CC=C(C=C1F)OCC2(CN(S(=O)(C3=CC=C(C=C3Cl)Cl)=O)C2)O

Molecular Formula

C17H13Cl2FN2O4S

Molecular Weight

431.27

References & Citations

[1]Jiang Y, et al. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol. 2022 Mar 24;15 (1) :34.|[2]Sarah Skerratt, et al. The Discovery and Optimisation of a Highly Selective Series of TRPV4 Antagonists.